3 recruiting. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 3 |
| Phase 2 | 1 | Recruiting 1 |
Follow Agitation: new trials by email Literature Review of Agitation trials Research Report on Agitation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) KarXT, KarX-EC - Alzheimer Disease, Agitation | Phase 3 | Recruiting | Bristol-Myers Squibb | 650 | 2025-12-02 | 2026-10-16 |
| Acute Agitation in Emergency Psychiatry Sublingual Dexmedetomidine, Buccal midazolam, Oral lorazepam - Agitation | Phase 2 / Phase 3 | Recruiting | Lone Baandrup | 132 | 2024-12-30 | 2025-01-01 |
| Nabilone for Agitation Blinded Intervention Trial Nabilone, Placebo - Alzheimer Disease, Agitation | Phase 3 | Recruiting | Sunnybrook Health Sciences Centre | 112 | 2021-02-01 | 2026-01-28 |
Psychomotor Agitation (3) · Alzheimer Disease (2) · Marijuana Abuse (1)
Aberrant Motor Behavior in Dementia (3) · Behavior (3) · Behavioral Symptoms (3) · Dyskinesias (3) · Nervous System Diseases (3) · Neurobehavioral Manifestations (3) · Neurologic Manifestations (3) · Pathological Conditions, Signs and Symptoms (3) · Psychomotor Disorders (3) · Signs and Symptoms (3) · Brain Diseases (2) · Central Nervous System Diseases (2) · Dementia (2) · Mental Disorders (2) · Neurocognitive Disorders (2)
Lorazepam (1) · nabilone (1) · xanomeline (1)
Bristol-Myers Squibb (1) · Lone Baandrup (1) · Sunnybrook Health Sciences Centre (1)
Canada (2) · Argentina (1) · Brazil (1) · Bulgaria (1) · Chile (1) · China (1) · Croatia (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · India (1) · Israel (1)
Giovanni Marotta, MD (1) · Krista L. Lanctot, PhD (1) · Lone Baandrup, MD, DMSc (1)
2023 (1)